Company: NCNA
Filing Date: 2025-05-02
Form Type: F-1/A
Source: 0001193125-25-110310
Chunk: 11

Company: NuCana plc
Filing Date: 2025-05-02
Form: F-1/A
Chunk 11
---
 medicines. While these conventional agents remain part of the standard of care for the treatment of many
solid and hematological tumors, they have significant shortcomings that limit their efficacy and they are often poorly tolerated. Utilizing our proprietary technology, we are developing new medicines, ProTides, designed to overcome the key
limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells. Our pipeline includes NUC-7738 and NUC-3373.

Corporate Information

We were
incorporated under the laws of England and Wales in 1997 under the name Biomed (UK) Limited, and commenced operations in 2008. On April 28, 2008, we changed our name to NuCana BioMed Limited. On August 29, 2017, we re-registered as a public limited company and changed our name to NuCana plc. On October 2, 2017, we completed our initial public offering of ADSs on The Nasdaq Global Select Market. On November 9, 2023,
we transferred our listing to The Nasdaq Capital Market. Our ADSs are traded under the symbol “NCNA”.

Our registered office is
located at 77/78 Cannon Street, London EC4N 6AF, United Kingdom. Our principal executive offices are located at 3 Lochside Way, Edinburgh, EH12 9DT, United Kingdom, our general telephone number is +44 (0)131 357 1111 and our internet address is
https://www.nucana.com. Our website and the information contained on or accessible through our website are not part of this prospectus. Our agent for service of process in the United States is Corporation Service Company, 251 Little Falls Drive,
Wilmington, DE 19808. The SEC maintains an internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC (http://www.sec.gov).

Recent Developments

On April 23, 2025,
we held a general meeting of our ordinary shareholders, or the GM, at Lochside House, 3 Lochside Way, Edinburgh, EH12 9DT, United Kingdom. All of the resolutions set out in our notice of the GM dated March 18, 2025 and furnished on Form 6-K with the
SEC on March 18, 2025 were duly proposed and passed, including the following resolutions:

1. As an ordinary resolution,